Skip to content

To Investigate predictors of the efficacies of biologics for rheumatoid arthritis or psoriatic arthritis

To Investigate predictors of the efficacies of biologics for rheumatoid arthritis or psoriatic arthritis - Predictors of the efficacies of biologics for rheumatoid arthritis or psoriatic arthritis

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
JPRN
Registry ID
JPRN-UMIN000023152
Enrollment
80
Registered
2016-07-14
Start date
2011-07-26
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid arthritis, Psoriatic arthritis

Interventions

None listed

Sponsors

Immune-Mediated Diseases Therapy Center, Graduate School of Medicine University of Tokyo
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Patients with rheumatoid arthritis or psoriatic arthritis who are treated with a first biologic or a switching biologic 2) Patients must be able to sign the informed consent.

Exclusion criteria

Exclusion criteria: 1) Patients who refuse to participate this study 2) Patients for whom the physicians do not think suitable for this study

Design outcomes

Primary

MeasureTime frame
To clarify predictors of the efficacies of biologics for rheumatoid arthritis or psoriatic arthritis

Secondary

MeasureTime frame
Correlation between functional of bone structural disease activity scores of rheumatoid arthritis or psoriatic arthritis and predictors

Countries

Japan

Contacts

Public ContactHiroko Kanda

University of Tokyo Immune-mediated Diseases Therapy Center, Graduate School of Medicine

hkanda-tky@umin.ac.jp03-3815-5411

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026